Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) rose 3.7% during mid-day trading on Wednesday . The stock traded as high as $21.40 and last traded at $21.31, with a volume of 218,045 shares traded. The stock had previously closed at $20.55.

SUPN has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Wednesday. Jefferies Group restated a “buy” rating and set a $23.00 price objective (up from $19.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, May 12th. TheStreet upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 29th. Northland Securities restated an “outperform” rating and set a $22.00 price objective on shares of Supernus Pharmaceuticals in a research report on Friday, March 11th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $24.00 price objective on shares of Supernus Pharmaceuticals in a research report on Saturday, April 2nd. Five analysts have rated the stock with a buy rating, Supernus Pharmaceuticals currently has an average rating of “Buy” and an average target price of $23.00.

The firm’s 50 day moving average price is $18.97 and its 200 day moving average price is $15.44. The company has a market capitalization of $1.07 billion and a price-to-earnings ratio of 63.85.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.09 by $0.01. The firm had revenue of $43 million for the quarter, compared to analyst estimates of $45.33 million. During the same quarter in the previous year, the business posted $0.02 earnings per share. The firm’s revenue for the quarter was up 53.0% on a year-over-year basis. On average, equities analysts anticipate that Supernus Pharmaceuticals Inc. will post $0.62 EPS for the current year.

In related news, VP Padmanabh P. Bhatt sold 30,762 shares of the business’s stock in a transaction dated Monday, April 11th. The shares were sold at an average price of $16.49, for a total value of $507,265.38. Following the sale, the vice president now directly owns 57,306 shares in the company, valued at approximately $944,975.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the stock. Whitebox Advisors LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $1,014,000. Numeric Investors LLC raised its position in Supernus Pharmaceuticals by 101.8% in the fourth quarter. Numeric Investors LLC now owns 78,500 shares of the specialty pharmaceutical company’s stock worth $1,055,000 after buying an additional 39,600 shares during the period. Cornerstone Capital Management Holdings LLC. raised its position in Supernus Pharmaceuticals by 15.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 123,600 shares of the specialty pharmaceutical company’s stock worth $1,662,000 after buying an additional 16,300 shares during the period. Marshall Wace LLP purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $2,345,000. Finally, New York State Common Retirement Fund raised its position in Supernus Pharmaceuticals by 3.7% in the fourth quarter. New York State Common Retirement Fund now owns 205,981 shares of the specialty pharmaceutical company’s stock worth $2,768,000 after buying an additional 7,299 shares during the period.

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.